AlphaMaven AlphaMaven

Investing in Boltz - Andreessen Horowitz

Reported by A16z
Nov 18, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • Andreessen Horowitz (a16z) announced its investment in Boltz, a public-benefit AI company building open-source biomolecular foundation models, as part of a $110M Series A round.
  • • Boltz reports that weekly molecular token consumption by its customers has risen roughly 50-fold in the last four months following the launch of BoltzMol-1 and BoltzProt-1, according to the company's own post.
  • • Boltz's commercial models are reportedly deployed at Pfizer, GSK, Takeda, and Bristol Myers Squibb, among other pharmaceutical companies.
  • • Boltz is pursuing a usage-based business model that charges for molecular token consumption while making its models broadly accessible to scientists.
  • • The company's earlier seed round, reported at $28M and co-led by a16z, Amplify Partners and Zetta Venture Partners, brought its total disclosed funding to date to the figures cited in public reporting.
Summary
Andreessen Horowitz published a post announcing its investment in Boltz, a company it describes as helping lead the shift toward AI-driven molecular design in drug discovery. The post, written by the firm, congratulates founders Gabriele Corso, Jeremy Wohlwend, and Saro Passaro on a $110 million Series A round and says the firm is doubling down on its investment. The firm states that it co-led Boltz's seed round the prior year, when the company's open-source models had reportedly reached every top 20 pharmaceutical company. Public reporting on the seed round cites $28 million, with investors including Amplify Partners, Zetta Venture Partners and a16z, plus angel investors.

Boltz originated as a research project at MIT and has built what the company calls the world's most widely adopted molecular models. Its platform lets scientists specify the properties a medicine requires, predict molecular interactions, generate molecules against defined criteria, and refine designs across multiple objectives before synthesis and testing. Boltz Lab provides a user interface for biologists and chemists, while the Boltz API integrates these capabilities into computational workflows and agentic tools such as Claude Code and Codex.

The company's commercial model centers on molecular tokens, units of molecular information processed by its models, which customers consume and pay for on a usage basis. Boltz says weekly token consumption has risen roughly 50-fold over the last four months following the launch of BoltzMol-1 and BoltzProt-1. It also offers exclusive versions of its models trained on partners' proprietary data. According to the company, its commercial models are deployed at Pfizer, GSK, Takeda, Bristol Myers Squibb and other large pharmaceutical companies. These figures are company-reported and have not been independently verified.

According to the company's post, the new capital will go toward research, compute and data to build more capable models.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

A16z Investing in Boltz - Andreessen Horowitz